Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.73 |
| ▸ | THRA | P10827 | 8/20 | 0.73 |
| ▸ | PPARG | P37231 | 6/20 | 0.73 |
| ▸ | RXRA | P19793 | 3/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.73 |
| ▸ | ITGAV | P06756 | 1/20 | 0.73 |
| ▸ | PCNA | P12004 | 9/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | TTR | P02766 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825994 | 0.91 | THRB (0.69) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL16425259 | 0.91 | PCNA (0.68) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL554462 | 0.86 | PCNA (0.62) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL12440046 | 0.86 | PCNA (0.69) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL1270234 | 0.85 | PCNA (0.57) | THRBTHRAPPARGRXRAITGB3 | |
| Tetrac SCHEMBL365951 | 0.84 | THRB (1.00) | THRBTHRAPPARGRXRAITGB3 | |
| Thyropropic Acid SCHEMBL310201 | 0.84 | PCNA (1.00) | THRBTHRAPPARGRXRAPCNA | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.84 | PCNA (1.00) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL14485308 | 0.82 | PCNA (0.77) | THRBTHRAPPARGRXRAITGB3 | |
| SCHEMBL17874460 | 0.82 | FFAR1 (0.64) | THRBTHRAPPARGRXRAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662079-A1 | Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells | Ordway Research Institute, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| EP-1594480-A4 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | UNIV ARIZONA (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2005123099-A2 | METHODS AND COMPOSITIONS FOR ACCELERATING ALCOHOL METABOLISM | ENZYMEDIX, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050272817-A1 | Dermatological use and a dermatological preparation | HEINO PEKKA | 2005-12-08 | — | — | US | claimed |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ENZYMEDIX | 2005-12-08 | — | — | US | claimed |
| EP-1594480-A1 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | The Arizona Board of Regents on Behalf of the University of Arizona (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004073694-A1 | METHOD TO TREAT CHRONIC HEART FAILURE AND/OR ELEVATED CHOLESTEROL LEVELS | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2004-09-02 | — | — | WO | claimed |
| US-6716877-B2 | Method to treat chronic heart failure and/or elevated cholesterol levels | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2004-04-06 | — | — | US | claimed |
| US-20030147815-A1 | Method to treat chronic heart failure and/or elevated cholesterol levels | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE | 2003-08-07 | — | — | US | claimed |
| US-20030144359-A1 | Dermatological use and a dermatological preparation | HEINO, PEKKA (FI) | 2003-07-31 | — | — | US | claimed |
| EP-1274416-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | Ipsat Therapies Oy (FI) | 2003-01-15 | — | — | EP | claimed |
| WO-2001076589-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | IPSAT THERAPIES OY (FI) | 2001-10-18 | — | — | WO | claimed |
| US-20210386699-A1 | LIQUID READY-TO-USE FORMULATION OF LEVOTHYROXINE | SOMERSET THERAPEUTICS LLC (US) | 2021-12-16 | — | — | US | disclosed |
| EP-2442800-B1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE, ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF | NANOPHARMACEUTICALS LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-20030147815-A1 | Method to treat chronic heart failure and/or elevated cholesterol levels | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE | 2003-08-07 | — | — | US | disclosed |
| US-20030144359-A1 | Dermatological use and a dermatological preparation | HEINO, PEKKA (FI) | 2003-07-31 | — | — | US | disclosed |
| EP-1274416-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | Ipsat Therapies Oy (FI) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001076589-A1 | DERMATOLOGICAL USE AND A DERMATOLOGICAL PREPARATION | IPSAT THERAPIES OY (FI) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272817-A1 | Dermatological use and a dermatological preparation | TPO, TYR, TRHDE | THRB 26/4885THRA 17/4885PPARG 259/4885 |
| US-20030144359-A1 | Dermatological use and a dermatological preparation | TPO, TYR, TRHDE | THRB 26/4885THRA 17/4885PPARG 259/4885 |
| US-20210386699-A1 | LIQUID READY-TO-USE FORMULATION OF LEVOTHYROXINE | TPO, TSHR, TRHR | THRB 12/4885THRA 6/4885PPARG 2329/4885 |
| US-20050271739-A1 | Methods and compositions for accelerating alcohol metabolism | ADH1A, ADH1C, ADH5 | THRB 2655/4885THRA 2112/4885PPARG 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.